Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2018

  • ID: 4464785
  • Report
  • 160 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4P-Pharma SAS
  • Aevi Genomic Medicine Inc
  • APeT Holding BV
  • Arcturus Therapeutics Ltd
  • BCWorld Pharm Co Ltd
  • BioHealthonomics Inc
  • MORE
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2018, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 11, 8, 16, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4P-Pharma SAS
  • Aevi Genomic Medicine Inc
  • APeT Holding BV
  • Arcturus Therapeutics Ltd
  • BCWorld Pharm Co Ltd
  • BioHealthonomics Inc
  • MORE
List of Tables

List of Figures

Introduction

The Publisher's Report Coverage

Attention Deficit Hyperactivity Disorder (ADHD) - Overview

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development

4P-Pharma SAS

Aevi Genomic Medicine Inc

Amarantus Bioscience Holdings Inc

APeT Holding BV

Arcturus Therapeutics Ltd

BCWorld Pharm Co Ltd

BioHealthonomics Inc

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Curemark LLC

DURECT Corp

Heptares Therapeutics Ltd

Highland Therapeutics Inc

IRLAB Therapeutics AB

KemPharm Inc

leon-nanodrugs GmbH

Merck & Co Inc

NeuroDerm Ltd

Novartis AG

Noven Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Otsuka Pharmaceutical Co Ltd

P2D Bioscience

RespireRx Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Shire Plc

SK Biopharmaceuticals Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Taisho Pharmaceutical Holdings Co Ltd

Tris Pharma Inc

Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles

(nicotine + opipramol hydrochloride) - Drug Profile

4-P003 - Drug Profile

atomoxetine hydrochloride - Drug Profile

BCWPE-003 - Drug Profile

BNC-375 - Drug Profile

CB-8411 - Drug Profile

centanafadine SR - Drug Profile

CM-4612 - Drug Profile

CX-717 - Drug Profile

dasotraline hydrochloride - Drug Profile

dexmethylphenidate hydrochloride - Drug Profile

dextroamphetamine - Drug Profile

dextroamphetamine - Drug Profile

dextroamphetamine IR - Drug Profile

dextroamphetamine MR - Drug Profile

eltoprazine - Drug Profile

fasoracetam - Drug Profile

guanfacine hydrochloride - Drug Profile

guanfacine hydrochloride ER - Drug Profile

histamine dihydrochloride - Drug Profile

HTL-1071 - Drug Profile

INV-107 - Drug Profile

KP-415 ER - Drug Profile

KP-484 - Drug Profile

Leon-02 - Drug Profile

levofacetoperane - Drug Profile

lisdexamfetamine dimesylate - Drug Profile

mazindol CR - Drug Profile

methylphenidate ER - Drug Profile

methylphenidate hydrochloride MR - Drug Profile

methylphenidate hydrochloride SR - Drug Profile

modafinil - Drug Profile

molindone hydrochloride ER - Drug Profile

niacinamide CR - Drug Profile

NLS-4 - Drug Profile

NLS-8 - Drug Profile

OPC-64005 - Drug Profile

P-001 - Drug Profile

PBF-509 - Drug Profile

PD-3044 - Drug Profile

PFR-08001 ER - Drug Profile

PFR-8026 - Drug Profile

RP-5063 - Drug Profile

SERx-480 - Drug Profile

SKL-13865 - Drug Profile

Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile

Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile

Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile

TRN-110 - Drug Profile

TS-141 - Drug Profile

viloxazine hydrochloride ER - Drug Profile

VU-0238429 - Drug Profile

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects

Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products

Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arcturus Therapeutics Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by IRLAB Therapeutics AB, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by leon-nanodrugs GmbH, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Novartis AG, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Holdings Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by RespireRx Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2018 (Contd..2), H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2018 (Contd..3), H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018 22

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4P-Pharma SAS
  • Aevi Genomic Medicine Inc
  • Amarantus Bioscience Holdings Inc
  • APeT Holding BV
  • Arcturus Therapeutics Ltd
  • BCWorld Pharm Co Ltd
  • BioHealthonomics Inc
  • Cingulate Therapeutics LLC
  • Collegium Pharmaceutical Inc
  • Curemark LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll